Science-Based, Passion-Driven

We are advancing an innovative, high-value product portfolio for patients globally.

Learn More
doctor_and_patient

Passion with Purpose

We work to benefit patients wherever they live by uniting worldwide talent and resources with our vision.

Learn More
people_walking

Our Commitment to Patients

We offer resources to help patients and their loved ones navigate some of the complex challenges that follow the words, “You have cancer.”

Learn More
elder_women

BeiGene News

October 4, 2024

BeiGene Announces Availability of TEVIMBRA® in U.S.

Read more

September 26, 2024

BeiGene Provides Update on FDA Advisory Committee Vote on Benefit-Risk Profile of PD-1 Inhibitors, including TEVIMBRA®, for Treatment of ESCC and Gastric/GEJ Cancers

Read more

September 26, 2024

Global Oncology Innovator BeiGene Appoints Shalini Sharp to Board of Directors

Read more

September 17, 2024

BeiGene Receives Israeli Ministry of Health Approval for TEVIMBRA® for the Treatment of Oesophageal Squamous Cell Carcinoma (OSCC) After Prior Chemotherapy

Read more

September 9, 2024

BeiGene Announces Updates to Commercial Leadership Team

Read more

September 9, 2024

BeiGene Highlights TEVIMBRA® Data in Lung and Gastrointestinal Cancers at ESMO 2024

Read more